Navigation Links
Arno Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/18/2008

FAIRFIELD, N.J., Aug. 18 /PRNewswire-FirstCall/-- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced financial results for the second quarter ended June 30, 2008.

Net loss was $3.8 million, or $0.29 per share, for the three months ended June 30, 2008, compared to $0.5 million, or $0.05 per share, for the same period in 2007. Net loss was $7.5 million, or $0.65 per share, for the six months ended June 30, 2008, compared to $0.8 million, or $0.08 per share, for the same period in 2007. Research and development expenses were $2.1 million and $5.3 million for the three and six months ended June 30, 2008, respectively. General and administrative expenses were $0.7 million and $1.2 million for the three and six months ended June 30, 2008. Cash used in operations was $4.9 million for the six months ended June 30, 2008.

At June 30, 2008, Arno had cash and cash equivalents of $14.4 million compared to $1.6 million on December 31, 2007. The increase in cash is attributed to the net proceeds of approximately $17.8 million resulting from Arno's June 2008 private placement of common stock.

"We are very pleased with the first half of the year results, as we continued to advance our Phase I lead compound AR-67, as well as in-license our two additional compounds AR-12 and AR-42," said Scott Z. Fields, MD, President and Chief Medical Officer of Arno. "With the additional capital from our June 2008 financing, we are excited to further advance the development of our three compounds."

Key Achievements for the Six Months Ended June 30, 2008

-- Expanded our product portfolio by in-licensing AR-12, a PDK1 inhibitor, and AR-42, a Pan-DAC inhibitor which also inhibits the Akt pathway

-- Appointed Arie S. Belldegrun, MD as Chairman of the Board of Directors

-- Appointed Robert I. Falk as member of the Board of Directors

-- Completed private placement of common stock, resulting in net proceeds of $17.8 million

-- Became a public reporting company as a result of the June 2008 merger with Laurier International, Inc.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel, third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR- 12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

ARNO THERAPEUTICS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED BALANCE SHEETS

June 30, 2008

(unaudited) December 31, 2007

ASSETS

Current assets

Cash and cash equivalents $14,412,517 $1,646,243

Prepaid expenses 122,999 74,092

Total current assets 14,535,516 1,720,335

Deferred financing fees, net - 13,541

Property and equipment, net 47,086 38,193

Security deposit 12,165 12,165

TOTAL ASSETS $14,594,767 $1,784,234

LIABILITIES AND STOCKHOLDERS' EQUITY

(DEFICIENCY)

Current liabilities

Accounts payable $856,948 $111,474

Accrued expenses 880,232 1,120,179

Due to related party 203,426 583

Convertible notes and accrued

interest payable - 4,179,588

TOTAL LIABILITIES 1,940,606 5,411,824

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY (DEFICIENCY)

Preferred stock, $0.0001 par value:

20,000,000 shares authorized,

0 shares issued and outstanding

at June 30, 2008 and December 31, 2007 - -

Common stock, $0.0001 par value:

80,000,000 shares authorized,

20,392,024 shares issued and

outstanding at June 30, 2008 and

9,968,797 shares issued and

outstanding at December 31, 2007 2,039 997

Additional paid-in capital 23,852,225 102,003

Deficit accumulated during the

development stage (11,200,103) (3,730,590)

TOTAL STOCKHOLDERS' EQUITY (DEFICIENCY) 12,654,161 (3,627,590)

TOTAL LIABILITIES AND STOCKHOLDERS'

EQUITY (DEFICIENCY) $14,594,767 $1,784,234

ARNO THERAPEUTICS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

For the For the For the For the

Three Three Six Six

Months Months Months Months

Ended Ended Ended Ended

June 30, June 30, June 30, June 30,

2008 2007 2008 2007

OPERATING EXPENSES

Research and

development $2,101,862 $401,402 $5,289,044 $612,199

General and

administrative 741,112 75,512 1,173,377 133,540

Total Operating

Expenses 2,842,974 476,914 6,462,421 745,739

LOSS FROM OPERATIONS (2,842,974) (476,914) (6,462,421) (745,739)

OTHER INCOME (EXPENSE)

Interest income 18,173 36,146 28,961 47,697

Interest expense (946,129) (64,550) (1,036,053) (97,808)

Total Other Income

(Expense) (927,956) (28,404) (1,007,092) (50,111)

NET LOSS $(3,770,930) $(505,318) $(7,469,513) $(795,850)

NET LOSS PER SHARE -

BASIC AND DILUTED $(0.29) $(0.05) $(0.65) $(0.08)

WEIGHTED AVERAGE SHARES

OUTSTANDING

- BASIC AND DILUTED 13,175,944 9,968,797 11,572,370 9,968,797

Cumulative Period from

August 1, 2005 (inception)

Through June 30, 2008

OPERATING EXPENSES

Research and

development $8,554,141

General and administrative 1,538,786

Total Operating Expenses 10,092,927

LOSS FROM OPERATIONS (10,092,927)

OTHER INCOME (EXPENSE)

Interest income 152,923

Interest expense (1,260,099)

Total Other Income

(Expense) (1,107,176)

NET LOSS $(11,200,103)

NET LOSS PER SHARE -

BASIC AND DILUTED

WEIGHTED AVERAGE SHARES

OUTSTANDING

- BASIC AND DILUTED


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):